156 related articles for article (PubMed ID: 37025490)
21. Ursodeoxycholic acid for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD000551. PubMed ID: 23235576
[TBL] [Abstract][Full Text] [Related]
22. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy of Chinese patent medicines for non-alcoholic fatty liver disease: A network meta-analysis.
Zhang L; Liu S; Gu Y; Li S; Liu M; Zhao W
Front Pharmacol; 2022; 13():1077180. PubMed ID: 36686656
[No Abstract] [Full Text] [Related]
24. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials.
Agrawal R; Majeed M; Attar BM; Omar YA; Mbachi C; Wang Y; Flores E; Shaqib S; Wang Y; Udechukwu V; Demetria M; Gandhi S
Ann Gastroenterol; 2019; 32(5):489-497. PubMed ID: 31474796
[TBL] [Abstract][Full Text] [Related]
26. Chinese patent medicine for functional dyspepsia effects: A protocol for systematic review and Bayesian network meta-analysis.
Wu J; Wei Y; Chen Y; Long Y; Huang N; Mei Y
Medicine (Baltimore); 2021 Nov; 100(47):e27761. PubMed ID: 34964734
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy and pharmacological mechanism of Chinese patent medicines against anthracycline-induced cardiotoxicity: An integrated study of network meta-analysis and network pharmacology approach.
Rao Y; Wang Y; Lin Z; Zhang X; Ding X; Yang Y; Liu Z; Zhang B
Front Cardiovasc Med; 2023; 10():1126110. PubMed ID: 37168657
[TBL] [Abstract][Full Text] [Related]
28. The Efficacy and Safety of Chinese Herbal Medicine in the Treatment of Knee Osteoarthritis: An Updated Systematic Review and Meta-Analysis of 56 Randomized Controlled Trials.
Lin Z; Zheng J; Chen M; Chen J; Lin J
Oxid Med Cell Longev; 2022; 2022():6887988. PubMed ID: 35035664
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: A meta-analysis of randomized controlled trials.
Li C; Wang P; Zhang L; Li M; Lei X; Liu S; Feng Z; Yao Y; Chang B; Liu B; Shang H
J Ethnopharmacol; 2018 Oct; 224():512-521. PubMed ID: 29860133
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis.
Guoyun X; Dawei D; Ning L; Yinan H; Fangfang Y; Siyuan T; Hao S; Jiaqi Y; Ang X; Guanya G; Xi C; Yulong S; Ying H
Front Pharmacol; 2022; 13():948362. PubMed ID: 36110537
[No Abstract] [Full Text] [Related]
31. Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review.
Suraweera D; Rahal H; Jimenez M; Viramontes M; Choi G; Saab S
Liver Int; 2017 Dec; 37(12):1877-1886. PubMed ID: 28517369
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy of different Chinese patent medicines in preventing restenosis after percutaneous coronary intervention: a systematic review and Bayesian network meta-analysis of randomized clinical trials.
Fan J; Li T; Pu F; Guo N; Wang J; Gao Y; Zhao H; Wang X; Zhu H
Front Pharmacol; 2023; 14():1265766. PubMed ID: 38249344
[No Abstract] [Full Text] [Related]
33. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
Ding D; Guo G; Liu Y; Zheng L; Jia G; Deng J; Sun R; Wang X; Guo C; Shang Y; Han Y
Hepatol Commun; 2022 Dec; 6(12):3487-3495. PubMed ID: 36213941
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis: A systematic review and meta-analysis.
Xu C; Yue R; Lv X; Wang S; Du M
Front Pharmacol; 2022; 13():835991. PubMed ID: 36339545
[No Abstract] [Full Text] [Related]
36. Effect of combined ursodeoxycholic acid and glucocorticoid on the outcome of Kasai procedure: A systematic review and meta-analysis.
Qiu JL; Shao MY; Xie WF; Li Y; Yang HD; Niu MM; Xu H
Medicine (Baltimore); 2018 Aug; 97(35):e12005. PubMed ID: 30170405
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
[TBL] [Abstract][Full Text] [Related]
38. Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitis.
Overi D; Carpino G; Cristoferi L; Onori P; Kennedy L; Francis H; Zucchini N; Rigamonti C; Viganò M; Floreani A; D'Amato D; Gerussi A; Venere R; Alpini G; Glaser S; Alvaro D; Invernizzi P; Gaudio E; Cardinale V; Carbone M
JHEP Rep; 2022 Nov; 4(11):100556. PubMed ID: 36267871
[TBL] [Abstract][Full Text] [Related]
39. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses.
Gong Y; Huang Z; Christensen E; Gluud C
Am J Gastroenterol; 2007 Aug; 102(8):1799-807. PubMed ID: 17459023
[TBL] [Abstract][Full Text] [Related]
40. [Network Meta-analysis of randomized controlled trials of Chinese patent medicine for bradyarrhythmia].
Hu HY; Ji ZC; Yu DD; Yang FW; Wang H; Zheng WK; Zhang JH
Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(5):1149-1158. PubMed ID: 32237459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
